Abbott (NYSE: ABT), a United States-based medical devices and health care company, has launched its NeuroSphere myPath, a digital health app, it was reported on Thursday.
The app aims to track and report patient perceived pain relief and general well-being associated with spinal cord stimulation or dorsal root ganglion therapy. During the device trial period required before the permanent implant, it enables patients to record their outcomes on pain and well-being while trialling their neurostimulation therapy.
The app can connect with Abbott support, access educational resources and track the progress of the patient's trial pain relief journey through their Apple mobile device. The NeuroSphere myPath will be available on the Apple App Store in the coming weeks and is expected to be available on Android devices in Q2 2021.
Aetna to launch generative AI-powered conversational experience
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Organon to sell JADA System to Laborie for up to USD465m
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
Oticon launches Oticon Zeal, a discreet, fully featured in-the-ear hearing aid
Halozyme Therapeutics announces Q3 2025 release date
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025